{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:35:14Z","timestamp":1761896114282},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.urology.2015.03.010","type":"journal-article","created":{"date-parts":[[2015,7,2]],"date-time":"2015-07-02T03:47:28Z","timestamp":1435808848000},"page":"57-61","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Intralesional Injections for Early Peyronie Disease: Standardized Assessment and Analysis of Predictive Factors for Treatment Response"],"prefix":"10.1016","volume":"86","author":[{"given":"Benoit","family":"Wolff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Peyronnet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanna","family":"Cattarino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Mozer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rapha\u00eble","family":"Renard-Penna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Ph\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc-Olivier","family":"Bitker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2015.03.010_bib1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.purol.2009.05.010","article-title":"Pathophysiology and management of Peyronie's disease in adult patients: an update","volume":"20","author":"Alenda","year":"2010","journal-title":"Prog Urol"},{"key":"10.1016\/j.urology.2015.03.010_bib2","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1071\/SH05031","article-title":"A\u00a0clinico-aetiological and ultrasonographic study of Peyronie's disease","volume":"3","author":"Kumar","year":"2006","journal-title":"Sex Health"},{"key":"10.1016\/j.urology.2015.03.010_bib3","first-page":"2350","article-title":"Subjective and objective analysis of the prevalence of Peyronie's disease in a population of men presenting for prostate cancer screening","volume":"171","author":"Mulhall","year":"2004","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2015.03.010_bib4","first-page":"285","article-title":"Proposal: trauma as the cause of the Peyronie's lesion","volume":"157","author":"Devine","year":"1997","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2015.03.010_bib5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.eururo.2012.05.040","article-title":"EAU Guidelines on Penile Curvature","volume":"62","author":"Wespes","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2015.03.010_bib6","first-page":"2221","article-title":"Surgical correction of Peyronie's disease via tunica albuginea plication or partial plaque excision with pericardial graft: long-term follow up","volume":"5","author":"Taylor","year":"2008","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.urology.2015.03.010_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.purol.2013.08.328","article-title":"Medical and surgical treatments of congenital and acquired penile curvature: a review","volume":"24","author":"Guillot-Tantay","year":"2014","journal-title":"Prog Urol"},{"key":"10.1016\/j.urology.2015.03.010_bib8","first-page":"1522","article-title":"Intralesional verapamil injection for the treatment of Peyronie's disease","volume":"151","author":"Levine","year":"1994","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2015.03.010_bib9","first-page":"1395","article-title":"Treatment of Peyronie's disease with intralesional verapamil injection","volume":"158","author":"Levine","year":"1997","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2015.03.010_bib10","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.urology.2007.02.042","article-title":"Intralesional verapamil prevents the progression of Peyronie's disease","volume":"69","author":"Bennett","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.urology.2015.03.010_bib11","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s11255-009-9522-4","article-title":"Effect of intralesional verapamil for treatment of Peyronie's disease: a randomized single-blind, placebo-controlled study","volume":"41","author":"Shirazi","year":"2009","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.urology.2015.03.010_bib12","first-page":"848","article-title":"Peyronie's disease intervention trials: methodological challenges and issues","volume":"6","author":"Muller","year":"2009","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.urology.2015.03.010_bib13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2011.10.033","article-title":"Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations","volume":"61","author":"Mitropoulos","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2015.03.010_bib14","series-title":"Sexual medicine: sexual dysfunction in men and women. 2nd international consultation on sexual dysfunction","first-page":"392","author":"Lue","year":"2004"},{"key":"10.1016\/j.urology.2015.03.010_bib15","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/sj.ijir.3900917","article-title":"Intralesional verapamil for the treatment of Peyronie's disease: a review","volume":"14","author":"Levine","year":"2002","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.urology.2015.03.010_bib16","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0090-4295(97)00700-0","article-title":"Use of intralesional verapamil to dissolve Peyronie's disease plaque: a long-term single-blind study","volume":"51","author":"Rehman","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.urology.2015.03.010_bib17","first-page":"621","article-title":"Experience with intraplaque injection of verapamil for Peyronie's disease","volume":"168","author":"Levine","year":"2002","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2015.03.010_bib18","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/j.1464-410X.2010.10029.x","article-title":"Defining predictors of response to intralesional verapamil injection therapy for Peyronie's disease","volume":"108","author":"Moskovic","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2015.03.010_bib19","first-page":"627","article-title":"Bother and distress associated with Peyronie's disease: validation of the Peyronie\u2019s disease questionnaire","volume":"190","author":"Hellstrom","year":"2013","journal-title":"J\u00a0Urol"},{"issue":"1 pt 2","key":"10.1016\/j.urology.2015.03.010_bib20","first-page":"414","article-title":"Standards for clinical trials in male sexual dysfunctions","volume":"7","author":"Porst","year":"2010","journal-title":"J\u00a0Sex Med"},{"key":"10.1016\/j.urology.2015.03.010_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/bju.12634","article-title":"Minimally invasive treatment of Peyronie's disease: evidence-based progress","volume":"114","author":"Jordan","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2015.03.010_bib22","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.purol.2011.06.009","article-title":"Clinical and para-clinical assessment of Peyronie's disease: place of questionnaires and penile duplex ultrasound","volume":"22","author":"Muyshondt","year":"2012","journal-title":"Prog Urol"},{"key":"10.1016\/j.urology.2015.03.010_bib23","first-page":"2115","article-title":"An analysis of the natural history of Peyronie's disease","volume":"175","author":"Mulhall","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2015.03.010_bib24","first-page":"1376","article-title":"The natural history of Peyronie's disease","volume":"144","author":"Gelbard","year":"1990","journal-title":"J\u00a0Urol"},{"issue":"suppl 5","key":"10.1016\/j.urology.2015.03.010_bib25","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1038\/sj.ijir.3901082","article-title":"Expanding the paradigm for plaque development in Peyronie's disease","volume":"15","author":"Mulhall","year":"2003","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.urology.2015.03.010_bib26","first-page":"394","article-title":"Single-blind, multicenter, placebo controlled parallel study to assess the safety and efficacy of intralesional interferon alpha-2B for minimally invasive treatment of Peyronie's disease","volume":"176","author":"Hellstrom","year":"2006","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2015.03.010_bib27","first-page":"380","article-title":"A\u00a0comparative study of the efficacy of intralesional verapamil versus normal saline injection in a novel Peyronie disease animal model: assessment of immunohistopathological changes and erectile function outcomes","volume":"189","author":"Chung","year":"2013","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2015.03.010_bib28","first-page":"2194","article-title":"Outcomes of intralesional interferon-\u03b12B for the treatment of Peyronie disease","volume":"190","author":"Trost","year":"2013","journal-title":"J\u00a0Urol"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429515002526?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429515002526?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T02:54:22Z","timestamp":1537498462000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429515002526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0090429515002526"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2015.03.010","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intralesional Injections for Early Peyronie Disease: Standardized Assessment and Analysis of Predictive Factors for Treatment Response","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2015.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}